Eli Lilly said that Yurpeak will be priced on par with Mounjaro — at ₹3,500 (MRP) for the 2.5 mg vial and ₹4,375 (MRP) for the 5 mg vial. (Source: File)
Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to distribute its blockbuster weight-loss drug Mounjaro. The drug, which was launched in India in March, will be sold by Cipla under a different brand name, Yurpeak, across the country.
The partnership is significant, as it allows Eli Lilly’s weight-loss drug to leverage Cipla’s extensive distribution footprint — reaching beyond the traditional large metros where Mounjaro is currently available. The company has described the agreement as “strategic,” coming just months before the primary patent for Novo Nordisk’s semaglutide (Wegovy) — a rival to tirzepatide (Mounjaro) — is set to expire in India in March next year. This expiry could pave the way for the launch of generic versions of semaglutide at significantly lower prices in the Indian market.
You have exhausted your monthly limit of free stories.
Read more stories for free with an Express account.
Eli Lilly said that Yurpeak will be priced on par with Mounjaro — at ₹3,500 (MRP) for the 2.5 mg dose and ₹4,375 (MRP) for the 5 mg dose. In comparison, Novo Nordisk’s Wegovy is priced higher, with its lower-dose variants — 0.25 mg, 0.5 mg, and 1 mg — costing around ₹17,345 per month, while the 1.7 mg and 2.4 mg doses are priced at ₹24,280 and ₹26,015 per month, respectively. This positions Wegovy as a slightly more expensive option than its rival Mounjaro, which is estimated to cost between ₹14,000 and ₹17,500 per month.
The future of collaboration
Significantly, this is not Eli Lilly’s first strategic tie-up with Cipla, India’s third largest pharma company. The US pharmaceutical giant has previously collaborated with the Indian firm on two of its diabetic products: Humalog and Trulicity.
The announcement also comes at a time when Cipla revamped its trade generics business with a new distribution model aimed at increasing direct engagement with retailers. As a result, in FY 2024-25, expanded its retail presence pan-India, reaching an estimated 1.5 lakh pharmacy and retail outlets, according to Cipla.
“Under the agreement, Cipla has the rights to distribute and promote Yurpeak—the second brand of tirzepatide in India. This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence,” the official statement said.
What is tirzepatide?
Tirzepatide is approved for chronic weight management in adults. It is indicated for individuals who are either obese (body mass index [BMI] of 30 or more) or overweight (BMI of 27 or more) and have at least one weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes. The drug is administered as subcutaneous injections and is intended to be used alongside a reduced-calorie diet and increased physical activity.
Story continues below this ad
This class of drugs is composed of polypeptides, small proteins that enhance naturally occurring hormones in the body. Tirzepatide works by increasing glucagon-like peptide-1 (GLP-1) levels, which regulate weight through effects on the brain and digestive tract. Higher GLP-1 levels, released in the gut, stimulate neurons that slow gut function and create a sense of fullness. At the same time, GLP-1 activates neural pathways in the brain that trigger satiety—the feeling of being satisfied after eating. The drugs also help manage glucose levels, making them effective for diabetes treatment.
Significantly, tirzepatide not only targets GLP-1 receptors but also enhances a second hormone: glucose-dependent insulinotropic polypeptide (GIP). This regulates weight through receptors in the brain and fat cells, and its combined action with GLP-1 amplifies the effects of both hormones, according to the company.
A wider access
“The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions,” said Winselow Tucker, president and general manager, Lilly India. “Our mission —to make life better for people around the world — drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities. With India facing a growing burden of type 2 diabetes and obesity, broader availability of tirzepatide will ensure that more patients can benefit from this innovative therapy.”
“At Cipla, we remain steadfast in our commitment to advancing patient care by facilitating access to the best of global scientific innovation. With the introduction of Yurpeak® (tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies. Our partnership with Lilly reflects our resolve to address one of the most pressing health concerns of our time and offer patients innovative, accessible solutions that can transform health outcomes,” said Achin Gupta, global chief operating officer, Cipla Limited.
Kaunain Sheriff M is an award-winning investigative journalist and the National Health Editor at The Indian Express. He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, an investigation into one of the world’s most powerful pharmaceutical companies.
With over a decade of experience, Kaunain brings deep expertise in three areas of investigative journalism: law, health, and data. He currently leads The Indian Express newsroom’s in-depth coverage of health.
His work has earned some of the most prestigious honours in journalism, including the Ramnath Goenka Award for Excellence in Journalism, the Society of Publishers in Asia (SOPA) Award, and the Mumbai Press Club’s Red Ink Award.
Kaunain has also collaborated on major global investigations. He was part of the Implant Files project with the International Consortium of Investigative Journalists (ICIJ), which exposed malpractices in the medical device industry across the world. He also contributed to an international investigation that uncovered how a Chinese big-data firm was monitoring thousands of prominent Indian individuals and institutions in real time.
Over the years, he has reported on several high-profile criminal trials, including the Hashimpura massacre, the 2G spectrum scam, and the coal block allocation case. Within The Indian Express, he has been honoured three times with the Indian Express Excellence Award for his investigations—on the anti-Sikh riots, the Vyapam exam scam, and the abuse of the National Security Act in Uttar Pradesh. ... Read More
